Cortechs.ai | OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

Prostate MRI has become an essential tool in prostate cancer detection and treatment planning. One of the greatest challenges in clinical imaging today is variability-differences in MRI platforms, field strengths, and acquisition approaches can influence image quality and diagnostic confidence. OnQ Prostate was initially implemented on GE and Siemens 3T systems in a research setting. With Cortechs.ai’s commitment to delivering clinically ready AI solution we have expanded to include Fuji, Canon, United, and Philips, on both 1.5T and 3T systems.

At Cortechs.ai, we believe advanced AI solutions must deliver consistent, reliable performance regardless of where or how they are deployed. That’s why vendor validation is a foundational element of OnQ Prostate.

Why Vendor Validation Matters

Vendor validation helps ensure that OnQ Prostate delivers dependable performance by confirming that:

  • Quantitative outputs remain reliable across supported MRI vendor platforms
  • Qualitative outputs are intuitive and clinically meaningful
  • Reports are clear, consistent, and suitable for routine clinical use and reimbursement

For AI-powered prostate imaging, vendor validation is not optional, it is essential for clinical trust and scalability.

Designed for Real-World, Multi‑Vendor Imaging

OnQ Prostate is built with real-world clinical environments in mind. Vendor validation testing confirms that when supported MRI input such as T2-weighted imaging and RSI diffusion-weighted imaging are provided, the software consistently generates high-quality, clinically usable outputs across vendor platforms.

Throughout validation testing, OnQ Prostate demonstrated reliable performance in generating:

  • Restricted Signal Maps
  • Color Fusion Maps
  • ADC and Trace-Weighted Images
  • Quantitative Prostate Reports

Clinical reviewers consistently found these outputs to be intuitive, legible, and easy to interpret, supporting efficient and confident prostate MRI review across imaging environments.

Supporting Clinical Confidence at Scale

Vendor validation helps ensure that OnQ Prostate delivers dependable qualitative and quantitative insight-even in diverse, multi‑vendor imaging environments. By reducing technical uncertainty, radiologists can focus on what matters most: interpretation, diagnosis, and patient care.

With OnQ Prostate, imaging teams benefit from:

  • Confidence in prostate MRI results especially diffusion weighted imaging
  • Consistent visualization across supported MRI vendors
  • A streamlined workflow that integrates seamlessly into everyday clinical practice

Advancing Quantified Prostate MRI

OnQ Prostate vendor validation reflects Cortechs.ai’s commitment to delivering clinically ready AI solutions, designed, tested, and validated for real-world use. Through rigorous vendor validation, OnQ Prostate demonstrates its readiness to support advanced prostate MRI across imaging platforms, helping clinicians move forward with confidence.

More Resources

06/08/2026

Cortechs.ai and TAC Center Celebrate One Year of Advancing Neuroimaging Innovation in Peru

TAC Centers Peru is celebrating one year of integrating the NeuroQuant® suite into clinical practice.

06/04/2026

SNMMI 2026: Advancing the Future of Quantitative PET in Dementia Imaging

At SNMMI 2026, Cortechs.ai showcased NeuroQuant® PET and the growing role of quantitative PET imaging in dementia care.

06/02/2026

Cortechs.ai Collaborates with Microsoft to Bring AI-Powered Imaging Insights Directly into Radiology Workflows

Cortechs.ai and Microsoft are partnering to help bring advanced AI-powered quantitative imaging directly into radiology workflows.

05/26/2026

Cortechs.ai Partners with ARJ Medical to Advance AI-Driven Neuro and Prostate Imaging in the Middle East

Cortechs.ai and ARJ Medical have partnered to expand access to AI-powered neuro and prostate imaging solutions across the Middle East.

05/26/2026

ASNR 2026 Highlights the Growing Role of Quantitative Imaging in Neurology

ASNR 2026 brought together leaders across neuroradiology, imaging AI, and neurological care to explore the future of quantitative imaging.

05/11/2026

Better Models, Better Care: Inside Our Latest Brain Tumor Update

Explore how NeuroQuant® Brain Tumor v2.1 advances AI-powered brain tumor segmentation and clinical workflows.
Scroll to Top